Treatment with the agonists (BMPs, nodal) or the antagonists (noggin, lefty, SB431542) had no effect on melanoma cell proliferation or cell cycle and did not sensitize melanoma cells for modern pharmacological agents (dabrafenib, trametinib), indicating that the effects of BMP and nodal were independent of oncogenes driving uncontrolled proliferation. Here, CLN5 is linked to melanoma.